Label Image (Lbl500907774)
Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7774
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
This information shows the Responder Rate (250% Reduction from Baseline) in Study 1, where a statistically significant difference was observed compared to placebo. The data includes a range of percentages from 0% to 39.6%.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This is a statistical analysis comparing the responder rate (250% reduction from baseline) of patients taking different doses of Levetiracetam and a placebo in Study 2: Period A. The chart shows the percentages of patients categorized as responders for each treatment group. Levetiracetam at 2000mg/day had a statistically significant higher responder rate compared to the placebo group.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This text presents data on the responder rate (>50% reduction from baseline) in Study 3. The responder rates for placebo (N=104) and Levetiracetam 3000 mg/day (N=180) are provided as percentages. It highlights that the responder rate for Levetiracetam 3000 mg/day was statistically significant compared to placebo.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
This text is providing information about the Responder Rate (50% Reduction from Baseline) in Study 4. The results show a responder rate of 44.6% for the placebo group and 45% for the Levetiracetam group. The Levetiracetam group was found to be statistically significant versus the placebo group. This data can be useful in evaluating the effectiveness of Levetiracetam compared to a placebo in this study.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This text provides information about the Responder Rate for all patients ages 1 month to < 4 years showing a >50% reduction from the baseline in Study 5. It compares Placebo with Lovetracatam, showing a statistically significant difference in effectiveness.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
This Figure 6 from Study 7 displays the Responder Rate for a 250% reduction from baseline in primary generalized tonic-clonic (PGTC) seizure frequency per week. The graph shows the percentage of responders in patients taking Placebo (N=84) and Levetiracetam (N=79), with the latter showing a statistically significant improvement over the former.*
Chemical Structure (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
